"officials would not want the embarrassment of having a health scare with one of the big China labels."
I think you mean to say 'another' one, they've been there before of course, and 100x worse than the Abbott scandal. They ended up executing a bunch of officials for it. Feihe is probably as dominant as it is now because it was main China label to not get caught up in it.
But you are exactly right, the Chinese authorities learned from the 2008 contamination scandal whereas I doubt the same can be said for the FDA. They probably can't change their stance even if they wanted to. They've allowed access to foreign products (but as far as I'm aware) they haven't really relaxed the tariffs on them. Which is why A2M has not been in any rush to start selling its IF there.
Ironic that the CCCP has a more free market than the USA on that one...
A2M Price at posting:
$5.85 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)